Skip to main content
SpringerLink
Log in

State of the Art in the Pharmacologic Treatment of Borderline Personality Disorder

  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

This article reviews the most recent studies of the pharmacologic treatment of borderline personality disorder (BPD). Although research continues using randomized controlled trials with a placebo arm as well as active medication, meta-analyses and systematic reviews have revealed that the use of any specific medication or medication class in BPD remains at best uncertain and inconclusive. Studies indicate that the selective serotonin reuptake inhibitors have fallen out of favor, and researchers have turned their attention to the study of mood stabilizers and atypical antipsychotics. Thus, it is not surprising that trends in prescribing appear to be shifting toward the use of these two classes over the selective serotonin reuptake inhibitors; yet we remain without any medication that has a specific indication for treatment of BPD or an indication for any symptom that is seen as part of the BPD syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Soloff PH: Pharmacotherapy of borderline disorders. Compr Psychiatry 1981, 22:535–543.

    Article  CAS  PubMed  Google Scholar 

  2. Zanarini MC, Frankenburg FR, Khera GS, Bleichmar J: Treatment histories of borderline inpatients. Compr Psychiatry 2001, 42:144–150.

    Article  CAS  PubMed  Google Scholar 

  3. Oldham JM, Bender DS, Skodol AE, et al.: Testing an APA practice guideline: symptom-targeted medication utilization for patients with borderline personality disorder. J Psychiatr Pract 2004, 10:156–161.

    Article  PubMed  Google Scholar 

  4. Baker-Glenn E, Steels M, Evans C: Use of psychotropic medication among psychiatric out-patients with personality disorder. The Psychiatrist 2010, 34: 83–86.

    Article  Google Scholar 

  5. •• Stoffers J, Völlm BA, Rücker G, et al.: Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev. 2010, 6:CD005653. This is the full Cochrane systematic review of the pharmacotherapy of BPD. It is a fascinating and thoroughly detailed document, but it may be easier to digest in the more condensed version by Lieb et al. [29••].

  6. •• National Institute for Health and Clinical Excellence (NICE). Borderline Personality Disorder, Treatment and Management. London: The British Psychological Society and The Royal College of Psychiatrists. Available at http://www.nice.org.uk/CG78. Accessed May 1, 2010. As part of the NICE Guideline, this is a thorough review of the psychopharmacologic treatment of BPD. The authors are fairly negative about the usefulness of pharmacologic treatment, but they do give, in the fuller version, guidelines on psychopharmacologic treatment and many details as to how they evaluated the existing literature.

  7. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Borderline Personality Disorder. Am J Psychiatry 2001, 158:1–52

    Article  Google Scholar 

  8. • Schulz SC, Zanarini MC, Bateman A, et. al.: Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. Br J Psychiatry 2008, 193:485–492. This is the largest clinical trial in terms of numbers of participants of BPD pharmacotherapy ever conducted. Unfortunately, the results are not impressive.

  9. • Linehan MM, McDavid JD, Brown MZ, et al.: Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2008, 69:999–1005. This study combined dialectical behavioral therapy plus medication or placebo. It re-creates clinical reality, in which most patients receive pharmacotherapy as well as psychosocial (psychotherapeutic) treatment. Both groups improved, and the active medication group improved more (but not significantly more) quickly.

  10. Shafti SS, Shahveisi B: Olanzapine versus haloperidol in the management of borderline personality disorder: a randomized double-blind trial. J Clin Psychopharm 2010, 30:44–47.

    Article  CAS  Google Scholar 

  11. • Pascual JC, Soler J, Puigdemont D, et al.: Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. J Clin Psychiatry 2008, 69:603–608. This is a negative study for an atypical antipsychotic. The only solidly positive RCT for an atypical antipsychotic is with aripiprazole (Nickel et al. [44]), with some contradictory evidence for olanzapine.

  12. Loew TH, Nickel MK, Muehlbacher M, et. al.: Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharm 2006, 26:61–66.

    Google Scholar 

  13. • Nickel MK, Loew TH: Treatment of aggression with topiramate in male borderline patients, part II: 18-month follow-up. Eur Psychiatry 2008, 23:115–117. This study complements this group’s previous study showing the effectiveness of topiramate in women.

  14. • Reich DB, Zanarini MC, Bieri KA: A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. Int Clin Psychopharm 2009, 24:270–275. This is another study that supports the effectiveness of mood stabilizers in the BPD population.

  15. • Ziegenhorn AA, Roepke S, Schommer NC, et.al. : Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharma 2009, 29:170–173. This is an intriguing study that revealed the effectiveness of clonidine. However, the effectiveness seemed restricted to patients who also had comorbid PTSD.

  16. Zanarini MC, Vujanovic AA, Parachini EA, et al.: Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology. J Personal Disord 2003, 17:233–142.

    Article  Google Scholar 

  17. Bogenschutz MP, Nurnberg HG: Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 2004, 65:104–109.

    Article  CAS  PubMed  Google Scholar 

  18. Villeneuve E, Lemelin S: Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. J Clin Psychiatry 2005, 66:1298–303.

    Article  CAS  PubMed  Google Scholar 

  19. Bellino S, Paradiso E, Bogetto F: Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study. J Clin Psychiatry 2006, 67:1042–1046.

    Article  CAS  PubMed  Google Scholar 

  20. Adityanjee, Romine A, Brown E, et al.: Quetiapine in patients with borderline personality disorder: an open-label trial. Ann Clin Psychiatry 2008, 20:219–226

    Google Scholar 

  21. van den Eynde F, Senturk V, Naudts K, et al.: Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. J Clin Psychopharm 2008, 28:147–155.

    Article  Google Scholar 

  22. Quitkin FM: Placebos, drug effects, and study design: a clinician’s guide. Am J Psychiatry 1999, 156: 829–836.

    CAS  PubMed  Google Scholar 

  23. Bellino S, Zizza M, Rinaldi C, Bogetto F: Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy. Can J Psychiatry 2006, 51:453–460.

    PubMed  Google Scholar 

  24. • Bellino S, Rinaldi C, Bogetto F: Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy Can J Psychiatry 2010, 55:74–81. This is another study (though open-label) exploring the effectiveness of combined psychotherapy and psychopharmacology. Length of treatment seemed to be the most important variable related to improvement.

  25. Bellino S, Paradiso E, Bozzatello P, Bogetto F: Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study. J Psychopharm 2010, 24:333–339.

    Article  CAS  Google Scholar 

  26. Arntz A, van den Hoorn M, Cornelis J, et al.: Reliability and validity of the borderline personality disorder severity index. J Person Disord 2003, 17:45–59.

    Article  Google Scholar 

  27. Miyaoka T, Furuya M, Yasuda H, et al.: Yi-gan san for the treatment of borderline personality disorder: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:150–154.

    Article  PubMed  Google Scholar 

  28. Binks CA, Fenton M, McCarthy L, et al.: Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev 2006, 25:CD005653.

    Google Scholar 

  29. •• Lieb K, Völlm B, Rücker G, et al.: Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry 2010, 196:4–12. This is the shorter, more concise, more accessible version of the Cochrane review (Stoffers et al. [5••]).

  30. Abraham PF, Calabrese JR: Evidenced-based pharmacologic treatment of borderline personality disorder: a shift from SSRIs to anticonvulsants and atypical antipsychotics? J Affect Disord 2008, 111:21–30.

    Article  CAS  PubMed  Google Scholar 

  31. Nosè M, Cipriani A, Biancosino B, et al.: Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials. Int Clin Psychopharm 2006, 21:345–353.

    Article  Google Scholar 

  32. Herpertz SC, Zanarini M, Schulz CS, et al.: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders. World J Biol Psychiatry 2007, 8: 212–244.

    Article  PubMed  Google Scholar 

  33. •• Mercer D, Douglass AB, Links PS: Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms. J Personal Disord 2009, 23:156–174. This is an excellent meta-analysis that limited itself to studying the outcomes for depression and anger symptoms. Mood stabilizers had the largest effect on anger, with a moderate effect on depression. Antidepressants had a moderate effect on anger but only a small effect on depression. Antipsychotics (particularly aripiprazole) had a moderate effect on anger but no effect on depression. It is worth comparing these results with those of Ingenhoven et al. [35•].

  34. Duggan C, Huband N, Smailagic N, et al.: The use of pharmacological treatments for people with personality disorder: a systematic review of randomized controlled trials. Personality Ment Health 2008, 2: 119–170.

    Article  Google Scholar 

  35. • Ingenhoven T, Lafay P, Rinne T, et al.: Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J Clin Psychiatry 2010, 71:14–25. This excellent meta-analysis found that antipsychotics have a moderate effect on cognitive-perceptual symptoms and a moderate to large effect on anger, while antidepressants have no significant effect on impulsivity or depressed mood but a small effect on anxiety and anger. Mood stabilizers had a very large effect on impulsivity, a large effect on anxiety, and a moderate effect on depressed mood. This study provides support for mood stabilizer use in BPD patients, and it is worth comparing and contrasting it with the Mercer et al. [33••] meta-analysis.

  36. • Díaz-Marsá M, González Bardanca S, Tajima K, et al.: Psychopharmacological treatment in borderline personality disorder. Actas Esp Psiquiat .2008, 36:39–49. This is a very thorough review that proposes updated algorithms for the pharmacologic treatment of the following temperamental dimensions found in BPD: impulsivity-aggression, emotion instability, cognitive-perceptual distortions, and anxiety-inhibition. It is in English.

  37. Saunders EFH, Silk K: Personality trait dimensions and the pharmacologic treatment of borderline personality disorder. J Clin Psychopharm 2009, 29: 461–267.

    Article  Google Scholar 

  38. Silk KR, Jibson MD (2010) Personality disorders. In: Rothschild AJ (ed) The Evidence-Based Guide to Antipsychotic Medications. Washington DC: American Psychiatric Publishing, Inc; 2010, pp 101–124

    Google Scholar 

  39. Zanarini MC, Stanley B, Black DW, et al.: Methodological considerations treatment trials for persons personality disorder. Ann Clin Psychiatry 2010, 22:75–83.

    PubMed  Google Scholar 

  40. Zanarini MC, Frankenburg FR, DeLuca CJ, et al.: The pain of being borderline: dysphoric states specific to borderline personality disorder. Harvard Rev Psychiatry 1998, 6:201–207.

    Article  CAS  Google Scholar 

  41. Silk KR, Jibson MD: Personality disorders. In The Evidence-Based Guide to Antidepressant Medications. Edited by Rothschild AJ. Washington DC: American Psychiatric Publishing, Inc; Inc; 2011, In press.

    Google Scholar 

  42. Bateman A, Zanarini MC: Personality disorders. In Cambridge Textbook of Effective Treatments in Psychiatry. Edited by Tyrer P, Silk KR. Cambridge, UK: Cambridge University Press; 2008, pp 659–681.

    Google Scholar 

  43. Rinne T, van den Brink W, Wouters L, et al. : SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 2002, 159: 2048–2054.

    Article  PubMed  Google Scholar 

  44. Nickel MK, Muehlbacher M, Nickel C, et al.: Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2006, 163:833–838.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

Dr. Silk has served as secretary-treasurer for the International Society for the Study of Personality Disorders.

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Michigan Medical School, Box 5769, Rachel Upjohn Building, 4250 Plymouth Road, Ann Arbor, MI, 48109-2700, USA

    Louis Feurino III & Kenneth R. Silk

Authors
  1. Louis Feurino III
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenneth R. Silk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenneth R. Silk.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Feurino, L., Silk, K.R. State of the Art in the Pharmacologic Treatment of Borderline Personality Disorder. Curr Psychiatry Rep 13, 69–75 (2011). https://doi.org/10.1007/s11920-010-0168-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-010-0168-9

Keywords

Search

Navigation